Despite significant R&D investments, pharma companies often underestimate the multifaceted challenges of bringing promising treatments to market – from securing favourable reimbursement to developing ...
Companies increasingly train AI models on therapy transcripts, often relying on terms of service that obscure data use to obtain assent. Because AI systems generate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results